Literature DB >> 12861047

Intrathecal B-cell clonal expansion, an early sign of humoral immunity, in the cerebrospinal fluid of patients with clinically isolated syndrome suggestive of multiple sclerosis.

Yufen Qin1, Pierre Duquette, Yiping Zhang, Michael Olek, Reng-Rong Da, John Richardson, Jack P Antel, Pierre Talbot, Neil R Cashman, Wallace W Tourtellotte, Hartmut Wekerle, Stanley Van Den Noort.   

Abstract

The development of somatically mutated memory and plasma B cells is a consequence of T cell-dependent antigen-challenged humoral immunity. To investigate the role of B cell-mediated humoral immunity in the initiation and evolution of multiple sclerosis (MS), we analyzed Ig variable heavy chain genes of intrathecal B cells derived from patients with a first clinical manifestation suggestive of MS. Sequences of Ig variable regions showed that B cells in the cerebrospinal fluid from most of these patients were clonally expanded and carried somatic hypermutated variable heavy chain genes. The mutations showed a high replacement-to-silent ratio and were distributed in a way suggesting that these clonally expanded B cells had been positively selected through their antigen receptor. In comparison, intrathecal B-cell clonal expansion often precedes both oligoclonal IgG bands and multiple magnetic resonance imaging lesions. Clinical follow-up study showed that patients with clonally expanded intrathecal B cells had a high rate of conversion to clinically definite MS. The findings provide direct evidence of recruitment of germinal center differentiated B lymphocytes into the central nervous system during the initiation of MS. These results indicate B cell-mediated immune response in the cerebrospinal fluid is an early event of inflammatory reaction in the central nervous system of MS. This procedure also provides a more sensitive method to evaluate the association of humoral immunity in the evolution of MS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12861047     DOI: 10.1097/01.lab.0000077008.24259.0d

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  31 in total

Review 1.  Development of anti-CD20 therapy for multiple sclerosis.

Authors:  Beatrix Bartok; Gregg J Silverman
Journal:  Exp Cell Res       Date:  2011-04-12       Impact factor: 3.905

Review 2.  Viruses and multiple sclerosis.

Authors:  Gregory P Owens; Don Gilden; Mark P Burgoon; Xiaoli Yu; Jeffrey L Bennett
Journal:  Neuroscientist       Date:  2011-12       Impact factor: 7.519

Review 3.  The role of B cells in multiple sclerosis: Current and future therapies.

Authors:  Austin Negron; Rachel R Robinson; Olaf Stüve; Thomas G Forsthuber
Journal:  Cell Immunol       Date:  2018-10-21       Impact factor: 4.868

4.  Polyclonal B-cell expansion in the cerebrospinal fluid of patients with pseudotumor cerebri.

Authors:  Reng-Rong Da; Grace Kao; Wen-Zhong Guo; Michael Olek; Sudhir Gupta; Yiping Zhang; Stanley Van Den Noort; Yufen Qin
Journal:  J Clin Immunol       Date:  2004-11       Impact factor: 8.317

Review 5.  Humoral immunity in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis.

Authors:  Anne H Cross; Jennifer L Stark
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 6.  B-cells and humoral immunity in multiple sclerosis. Implications for therapy.

Authors:  Sangjin Oh; Cornelia Cudrici; Takahiro Ito; Horea Rus
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

7.  CSF IgG heavy-chain bias in patients at the time of a clinically isolated syndrome.

Authors:  Jeffrey L Bennett; Kurt Haubold; Alanna M Ritchie; Sydni J Edwards; Mark Burgoon; Andrew J Shearer; Donald H Gilden; Gregory P Owens
Journal:  J Neuroimmunol       Date:  2008-06-10       Impact factor: 3.478

8.  Peripheral VH4+ plasmablasts demonstrate autoreactive B cell expansion toward brain antigens in early multiple sclerosis patients.

Authors:  Jacqueline R Rivas; Sara J Ireland; Rati Chkheidze; William H Rounds; Joseph Lim; Jordan Johnson; Denise M O Ramirez; Ann J Ligocki; Ding Chen; Alyssa A Guzman; Mark Woodhall; Patrick C Wilson; Eric Meffre; Charles White; Benjamin M Greenberg; Patrick Waters; Lindsay G Cowell; Ann M Stowe; Nancy L Monson
Journal:  Acta Neuropathol       Date:  2016-10-11       Impact factor: 17.088

Review 9.  [Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis].

Authors:  H-P Hartung
Journal:  Nervenarzt       Date:  2009-12       Impact factor: 1.214

Review 10.  B cells in multiple sclerosis.

Authors:  Mark P Burgoon; Donald H Gilden; Gregory P Owens
Journal:  Front Biosci       Date:  2004-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.